ArticleEndocrine, metabolic & immune disorders drug targets2026
Modified Fuzi Lizhong Decoction Alleviates Colonic Lesions and Modulates Gut Microbiota in Diabetic Gastroparesis.
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiabetic gastroparesis (DGP) is a debilitating complication of diabetes mellitus. This study investigated the therapeutic effects of Modified Fuzi Lizhong decoction (MFZLZD) on DGP.
methodsA DGP rat model was established through a high-fat diet combined with an irregular feeding schedule. Rats were treated with MFZLZD (5 or 20 g/kg) or mosapride (positive control; 1 mL/100 g) for 7 weeks. Body weight and gastric parameters (gastric emptying, peristalsis, and blood flow) were assessed. Histopathological alterations in gastric and colonic tissues were evaluated via HE staining, while goblet cell density was quantified by AB-PAS staining. The expression of tight junction proteins was analyzed using immunofluorescence. Finally, 16S rRNA sequencing of fecal samples was performed to characterize alterations in the gut microbiota.
resultsMFZLZD significantly increased body weight and effectively restored gastric function in DGP rats. Moreover, MFZLZD treatment attenuated gastric and colonic mucosal injury, preserved goblet cell populations, and upregulated tight junction protein expression. Gut microbiota diversity was altered in DGP rats and was partially restored following MFZLZD treatment. Changes in 33 key microbial taxa were observed between groups. DISCUSSION: MFZLZD improved gastric function and reinforced intestinal barrier integrity in DGP rats. The observed changes in gut microbiota composition suggest a potential association between alterations in the gut microbiota and the therapeutic effects of MFZLZD, although the underlying mechanisms remain unclear and require further investigation.
conclusionMFZLZD represents a promising therapeutic strategy for DGP and is associated with improvements in intestinal barrier integrity, gastric function, and gut microbiota composition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.